Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma

Fig. 2

Transcriptional expression level and prognosis value of CDC6 in glioma from TCGA database. A-I The mRNA expression levels of CDC6 were analyzed in glioma patients according to (A) Age, (B) Gender, (C) Race, (D) IDH status, (E) 1p/19q codeletion, (F) WHO grade, (G-I) histological type, respectively. J-O Overall survival analysis towards the CDC6 expression was performed in subgroups of glioma patients: (J) Age: > 60, (K) Gender: Female, (L) primary therapy outcome: PD, (M) histological type: Glioblastoma, (N) IDH status: WT, (O) 1p/19q codeletion: non-codel. TCGA, The Cancer Genome Atlas; IDH, isocitrate dehydrogenase; WHO, World Health Organization; PD, progressive disease; WT, wild-type. ns, p ≥ 0.05, ***p < 0.001

Back to article page